| CLEMENT-DUCHENE, Christelle |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
RADIO-RYTHMIC, NCT04731610: Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma |
|
|
| Recruiting | N/A | 314 | Europe | Radiotherapy, Surveillance after resection | Institut Curie | Thymoma Malignant Recurrent | 02/25 | 03/29 | | |
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. |
|
|
| Recruiting | N/A | 250 | Europe | Molecular monitoring by quantification of cell-free DNA | University Hospital, Strasbourg, France | NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA | 05/25 | 10/27 | | |
| MORO-SIBILOT, Denis |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Completed | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
| Active, not recruiting | 1/2 | 73 | Europe | PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed | PDC*line Pharma SAS | Non Small Cell Lung Cancer | 07/24 | 12/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET |
|
|
| Active, not recruiting | 1 | 95 | Europe, US, RoW | elzovantinib (TPX-0022) | Turning Point Therapeutics, Inc. | Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations | 01/24 | 03/26 | | |
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
|
|
| Terminated | 1 | 28 | Europe, RoW | BBP-398, sotorasib | Navire Pharma Inc., a BridgeBio company, Amgen | Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer | 08/24 | 08/24 | | |
| Recruiting | N/A | 900 | Europe | | Centre Leon Berard | Carcinoma, Non-Small-Cell Lung | 03/26 | 12/26 | | |
| COURAUD, Sébastien |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
| Withdrawn | 2b | 250 | Europe | DILTIAZEM TEVA 60 mg or placebo | Hospices Civils de Lyon, Signia Therapeutics | COVID-19 | 10/24 | 12/24 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Completed | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
| Recruiting | 2 | 80 | Europe, RoW | Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736 | Centre Leon Berard, Groupe Français de Pneumo-Cancérologie | Large Cell Neuroendocrine Carcinoma of the Lung | 09/28 | 09/29 | | |
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer |
|
|
| Not yet recruiting | 2 | 152 | Europe | Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance) | Intergroupe Francophone de Cancerologie Thoracique | Stage III NSCLC | 09/28 | 01/32 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
| Completed | N/A | 140 | Europe | Blood sample, Low or upper respiratory tract sample, Stool collection or fecal swab, phone call | Hospices Civils de Lyon | Infection, Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 | 05/22 | 05/22 | | |
| Terminated | N/A | 65 | Europe | Questionnaires, blood test, Maximal effort test, actigraphy, Neuromuscular evaluation, stool analysis, food diary | Centre Hospitalier Universitaire de Saint Etienne, University of Saint-Etienne, Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques | Chronic Fatigue Syndrome, Intensive Care Unit, Muscle | 07/21 | 08/21 | | |
LUTON, NCT04957602: Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells) |
|
|
| Terminated | N/A | 6 | Europe | Blood collection | Hospices Civils de Lyon | Non Small Cell Lung Cancer | 09/22 | 09/22 | | |
DEEP-Lung-IV, NCT04994795: Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | N/A | 4000 | Europe, Canada, US, RoW | Predictive models (data collection) | Sophia Genetics SAS | Non-small Cell Lung Cancer Metastatic | 12/24 | 02/25 | | |
MADMAS, NCT05091190: Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers |
|
|
| Recruiting | N/A | 60 | Europe | Blood draws | Hospices Civils de Lyon | Metastatic NSCLC, Metastatic Head and Neck Cancer | 10/28 | 10/28 | | |
| Recruiting | N/A | 600 | Europe | Solicitation for lung cancer screening, added exams to the usual lung cancer screening | Hospices Civils de Lyon | Lung Cancer | 09/24 | 09/24 | | |
INOVOLINE, NCT05472532: Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture) |
|
|
| Recruiting | N/A | 132 | Europe | Patient sampling. | Hospices Civils de Lyon | Cancer Metastatic, Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Gastric Cancer | 12/24 | 12/24 | | |
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients |
|
|
| Recruiting | N/A | 580 | Europe | EGFR gene mutation analysis on liquid biopsy | Institut Bergonié, AstraZeneca | Non Small Cell Lung Cancer, Advanced Solid Tumor | 01/25 | 01/26 | | |
SyPoCo, NCT05805566: Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes |
|
|
| Recruiting | N/A | 750 | Europe | Blood collection | Hospices Civils de Lyon | Post-Covid Syndrome | 04/29 | 04/29 | | |
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy |
|
|
| Recruiting | N/A | 100 | Europe | Tele-monitoring | Hospices Civils de Lyon | Melanoma, Lung Cancer, Renal Cancer | 11/28 | 11/28 | | |
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE |
|
|
| Recruiting | N/A | 2000 | Europe | Estimation of the incidence of the irAE | Hospices Civils de Lyon | Cancer | 07/29 | 07/29 | | |
| Recruiting | N/A | 4000 | Europe | Quality of life questionnaire, Blood sample | Hospices Civils de Lyon | Lung Cancer | 05/32 | 05/42 | | |
SMALLHAN, NCT05523583: Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer |
|
|
| Recruiting | N/A | 165 | Europe | questionnaire, Tabacco and alcohol questionnaires | Hospices Civils de Lyon, International Agency for Research on Cancer | Lung or Head and Neck Cancer | 10/25 | 10/25 | | |
